Price Chart

Executive Summary

Teva announced a stalking-horse bid to acquire BioXcel Therapeutics' IGALMI (dexmedetomidine sublingual film) and related assets for $57.5M upfront plus up to $67.5M in contingent payments, through a court-supervised bankruptcy sale. The asset is under FDA review for at-home use in agitation associated with schizophrenia or bipolar disorder, with a PDUFA date of November 14, 2026. If approved, this would be the first FDA-approved at-home treatment for this condition, expanding Teva's psychiatry portfolio.

Key Financial Metrics

Key Facts

• Teva is the stalking-horse bidder for BioXcel Therapeutics' IGALMI (dexmedetomidine sublingual film) in a Section 363 bankruptcy sale.
• Upfront payment of $57.5 million plus up to $67.5 million in contingent payments tied to FDA approval timing and sales milestones.
• PDUFA target action date for at-home use approval is November 14, 2026.
• If approved, IGALMI would be the first FDA-approved at-home treatment for agitation associated with schizophrenia or bipolar I/II disorder.
• Transaction remains subject to bankruptcy court approval, potential higher bids, and customary closing conditions.
• Teva would receive a break-up fee and expense reimbursement if not the successful bidder.

Financial Impact

Up to $125 million total consideration ($57.5M upfront + $67.5M contingent), with potential for significant upside if approved and commercialized.

Risk Factors

• Bankruptcy court may approve a higher bid from another party.
• FDA may not approve the at-home use indication by the PDUFA date or at all.
• Contingent payments depend on approval timing and sales milestones, which are uncertain.
• Integration and commercialization risks if the deal closes.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status